Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 1(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09CCLLIINNIICCAALLIINNVVEESSTTIIGGAATTIIOONNPPLLAANN((CCIIPP))
INVESTIGATIONAL DEVI CE:
Mepilex Border Post -Op Ag
INVESTIGATION TITLE:
A single center, open, non -controlled 
investigation to evaluate the performance of a 
flexible, self -adherent absorbent silver dressing 
coated with a soft silicone layer after elective 
primary total hip or knee arthroplasty
CO-ORDINA TING INVESTIGA TOR:
Dr. Steven Myerthall
Cent er for Orthopedic Research and 
Education, Inc. d/b/a The CORE Institute
18444 N. 25th Avenue
Suite 320
Phoenix, Arizona 85023
MÖLNLYCKE C LINICAL ST UDY 
MANAGER:
Tina Kjellén
Mölnlycke Health Care
P.O Box 130 80
402 52 Go thenburg, Sweden
Phone: +46 31 722 30 98

Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 2(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09CLINICAL INVESTIGATION PLAN ( CIP) SYNOPSIS
INVESTIGATION TITLE : 
A single center, open, non -control led investigation to evaluate the performance of 
a flexible, self -adherent absorbent silver dressing coated with a soft silicone lay er 
after elective primary total hip or knee arthro plasty
Objectives
This investigation is undertaken to investigate the performance of a self -adhesive absorbent 
post-operative silver dressing coated w ith a soft silicone layer in subjects undergoing ele ctive
primary total hip or knee arthroplasty
The prim ary objective and outcome variable are show n in the table below ::
Primary objective Primary outcome v ariable
To evaluate the skin damage under 
the dressing from operation day to 
last visitDamage to the incision and surrounding skin 
from operation day to last visit in terms of:
-Blistering 
-Redness 
-Maceration 
The secondary objectives and outcome variables areshow n in the table below :
Secondary objectiv e Secondary outcome variable
To evaluate per formance of the 
dressing from operation day to last 
visit-Leakage 
-Show er ability 
-Dressing sticks to the staples/w ound 
closure strips/sutures 
-Bleeding caused by the dressing 
removal 
-Dressing w ear time (days)
-Number of dressing changes
-Residuals of the d ressing material in 
the wound or surrounding skin
-Dressing capacity of handling blood
To evaluate c omfort, conformability 
and acceptability of the dressing from 
operation day to last visitNurse/Investigator evaluation 
-Easeof application of the dressin g
-Ease of removal of the dressing
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 3(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09-Conform ation to the body contours
-Overall experience (only at the last 
visit)
Subject evaluation 
-Comfort w hen w earing the dressing
-Ease of mobility 
-Overall experience of the dressing 
(only at the last visit)
To evaluate pain at dressing removal 
from operation day to last visit-Millimeter reading on visual analogue 
scales (VAS) filled in by subject
The safety objective and outcome variables areshown in the table below :
Safety objective Safet y outcome v ariable
To eval uate safety of Mepilex Border 
Post-Op Ag by assessment of device 
deficiencies and adverse events, non -
serious and serious, rated for 
causality-Incidence of AE/ADE/SAE/SADE/DD
-Incidence of AE/ADE/SAE/SADE/DD 
leading to withdraw al
Overall Design  
This descriptive, prospective, non -controlled clinical investigation will be conducted on 
approximately 20 enrolled subjec ts at onesite in theUS.
The target subject saremale or female, 18 years and older , undergoing elective prim ary hip or 
knee arthroplasty with a possibility to participate in a follow -up visit 7 days after surgery.
Subjects w illconsecutively be allocated to a subject ID. The subjects w ill be follow ed 1-3 days 
after surgery and scheduled for a follow -up visit 7 days after surgery.
Study Pe riod
Estimated date of first subject enrolled Q12017
Estimated date of last subject com pleted Q22017
Estimated date of end of clinical investigation (database lock) is Q22017
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 4(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09Inclusion Criteria
For inclusion in the investigation, the subjects must f ulfillall of the belowcriteria prior to 
enrol lment: 
Screening Phase:
1.Age ≥18 years
2.Available for a follow -up visit including dressing change 7 days after surgery
3.Plan for elective primary hip or knee arthroplasty
4.Plan for incision size ≤18 cm
5.Provision of informed consent i.e. subject must be able to understand and sign the 
Patient Information and Consent Form
Enrol lment Phase (Day of surgery) ::
6.Undergoing elective primary hip or knee arthroplasty
Exclusion Criteria
Subject swho meet any of the below criteria will be excluded f rom the investigation:
Screening Phase:
1. Known allergy/hypersensitivity to any of the components of the dressing
2.Multi -trauma
3.Undergoing a rthroplasty due to tumo r 
4.Previous incision at the same knee or same side of the hip
5.Wound at t he surgical site prior to surgery
6.Neurological deficit of operated side (hemiplegia, etc.)
7.Documented skin disease at time of enrol lment, as judged by the investigator
8.Previously enrolled in the present investigation
9.Inclusion in other ongoing investigatio ns at present that would preclude the subject from 
participating in this investigation as judged by the investigator
10.Involvement in the planning and conduct of the clinical investigation (applies to all MHC
staff, investigational site staff andthird party vendor)
Enro llment Phase (Day of surgery) :
11.Dressing size does not fit the incision size (>18 cm)
12.Complications that w ould increase w ound risks if investigational dressing is applied
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 5(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09Schedule of Assessment
Day Baseline 
(screening 
visit)Day 0
Day of 
surge ryDay 
1
1st
post 
-op 
dayDay 
2
2nd
post-
op 
dayaDay 
3
3rd
post-
op 
dayaUnscheduled 
visitbDay 7
7th
post-op 
dayTermination
Visit window/days -21 to 0 0 0 0 0 0 -2 to 0c0
Visit (number) 1 2 3 4 5 Unscheduled 6 Termination
Inclusion /Exclusion 
Criteria 
InformedConsent 
Subject ID 
Subject demography 
Skin status atincision 
site
Medical /Surgical history 
Type of surgery 
Surgical incision 
condition     
Performance of the 
dressing     
Dressing logd () () ()  
Medication Log       
Pain assessmente() () ()  
Photo sf     
Nurse/investigator 
evaluationg     
Subject evaluationh    
Reason for termination 
AE/ADE /SAE/SADE /DD       
a Information will be collected at Day 3 only if the subject is still at the hospital and hasn´t been discharged
b If the dressing is changed prior to post -op day 7 and outside scheduled visits, an unscheduled vis it will be performed.
c When possible, visit 6 should be scheduled to post -op day 7. W hen not possible due to weekends, post- op day 5 or post -op day 6 could be scheduled. 
d Dressing application/change /removal will be documented in the Dressing log. Abilit y to stay on (curl up at edges and partial/complete detachment) will also be 
collected 
e Pain assessment at dressing removal (VAS). If a dressing change is deemed necessary prior to visit 6, pain assessment should be collected
f Photo s should be taken at vi sit 2 ( at the incision before application of the dressing, at dressing after application of the dressing) and if the dress ing is changed at 
visit 3 -6  ( at the dressing before removal of the dressing, at the incision after removal of the dressing and at dressing ( side facing the incision) , if signs of 
infection and if there in an unscheduled visit
g The nurse or the investigator will give their assessment concerning the treatment
hThe nurse or the investigator will collect the subject´s experience via interview
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 6(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09If the subject is discharged prior to post -op day 2 , visit 4 and 5 will not be perf ormed.
An occurrence of an AE/ADE/SAE/SADE/DD can be documented viaphotos at any time . 
Photos shall include a sticker marked w ith subject ID and visit number/d ate within the 
photograph . All photos w ill be checked (inspected) by Mölnlycke Health Care (MHC) personnel.
Details regarding variables to be collected are to be found in Appendix C .
Investigational Dev ice
Mepilex Border Post -Op Ag is a soft silicone foa m dressing that absorbs exudates, maintains a 
moist w ound healing environment and has antim icrobial properties . The investigational device is 
a line extension under current Mepilex Border Ag 510(k) clearance (K100029).
Mepilex Border Post -Op Ag consists of a Safetac®soft silicone wound contact layer, an 
absorbent polyurethane foam pad containing a silver compound and activated carbon, a layer 
with super absorbent polyacryl ate fiber s, a non -woven an d a vapor permeable w aterproof film.
The silicone layer is covered w ith a polyethylene release film w hich is in three parts with grip 
edges for easy application .
The dressing is steriliz ed in ethylene oxide (EO). Further details can be found in appendix D.
For this clinical investigation, M epilex Border Post -Op Ag w ill be available in the following size: 
Device (cm) Wound pad (cm) Border (cm)
10x25 5x20 2.5
No comparator will be used in this investigation.
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 7(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09TABLE OF CONTENTS
1.INTRODUCTION ................................................................................................ .....10
1.1 Risk/benefit Assessment ................................................................................................ ................... 11
2.OBJECT IVES ................................................................................................ ......... 12
3.CLINICAL INVESTIGATO R(S) A ND INVESTIGATI ON ADMI NISTRA TIVE 
STRUCTURE ................................................................................................ ................ 13
3.1 Staff at Investigation site(s) ............................................................................................................... 13
3.2 Mölnlycke Investigation Personnel ................................................................ ................................ ..13
3.3 Other Participants ................................................................................................ ............................... 14
4.INVESTIGATION  PLAN A ND PROCEDURES ................................ ....................... 14
4.1 Overall Design ................................................................................................................................ ......14
4.2 Procedures and Assessments ................................ ................................................................ .......... 14
4.2.1 Schedule of Assessment ................................................................................................ .................. 15
4.3 Selection of Population for Investigation ................................................................ ........................ 16
4.3.1 Inclusion Criteria ................................ ................................................................................................ 16
4.3.2 Exclusion Criteri a................................................................................................ ............................... 17
4.3.3 Withdrawal of Subjects from Treatment or Assessment ................................................................ .17
4.4 Investigational Device ................................................................................................ ........................ 18
4.4.1 Summary description of the Investigational Device(s) ................................................................ ....18
4.4.2 Labelling ................................................................ ................................................................ ............. 18
4.4.3 Accountab ility................................................................................................ ................................ .....18
4.4.4 Storage conditions ................................ ............................................................................................. 19
4.4.5 Method of Assigning Subjects to T reatment Groups ................................................................ ......19
4.5 Concomitant Treatments ................................ ................................................................ .................... 19
4.6 Performance and Safety ................................................................................................ ..................... 19
4.6.1 Subject Characteristics ................................................................................................ ..................... 19
4.6.2 Performance Measurements and Variables ................................................................ .................... 20
4.6.3 Safety Measurements and Variables ................................................................ ............................... 21
4.6.4 Anticipated ADEs ................................................................................................ ............................... 21
4.7 Data Quality Assurance ................................................................................................ ...................... 22
4.7.1 Monitoring, Audits and Inspections ................................................................ ................................ ..22
4.7.2 Training of Staff ................................................................ ................................................................ .22
4.7.3 Data Management ................................ ............................................................................................. 22
4.8 Statistical M ethods and Determination of Sample Size ................................................................ 23
4.8.1 Statistica l Evaluation ................................................................................................ ......................... 23
4.8.2 Determination of Sample Size ................................ ................................................................ .......... 24
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 8(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 094.9 Changes to the Clinical Investigation Plan ................................................................ ..................... 24
5.STATEMENTS OF COMPLI ANCE ................................................................ ......... 24
5.1 Ethics ................................................................................................................................ ..................... 24
5.1.1 Ethics review ................................................................................................................................ ......24
5.1.2 Ethica l Conduct of the Investigation ................................ ................................................................ .24
5.1.3 Patient Information and Consent Form ................................................................ ............................ 24
5.2 Regulatory and standards ................................ ................................................................ ................. 25
5.2.1 Regulatory review ................................................................................................ .............................. 25
5.2.2 Standards and other ................................ ................................................................ .......................... 25
5.2.3 Subject Data Protection ................................ ................................................................ .................... 25
5.3 SUBJECT PROTECTION PROCEDURES ................................................................ ......................... 25
5.3.1 Procedures in Case of  Medical Emergency ................................................................ .................... 25
5.3.2 Insurance ................................................................................................ ................................ ........... 25
6.INVESTIGATION  TIMET ABLE AND TERMINATION ................................ ............ 25
7.LITERATURE REVIEW AN D REFERENCES ................................ ........................ 26
8.DEFINITIONS AND PROCEDU RES FOR REPORTING OF ADVERSE EVENT, 
ADVERSE DEVICE EFFEC T, SERIOUS ADVERSE E VENT, SERIOUS ADVERS E 
DEVICE EFFECT AND DE VICE DEFICIENCY ................................ ............................. 27
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 9(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09LIST OF APPENDICES
Appendix A F-449 Clinical Investigation Plan Appendix A, Core Signatures
Appendix B F-173 Patient Information and Consent Forms
Appendix C F-542 All variables to be obtained during the Investigation
Appendix D Instructions for Use 
Appendix E Guide for Digital Photography 
LIST OF ABBREVIATION S 
ADE Adverse Dev ice Effect
AE Adverse Ev ent
CA Competent Authority
CIP Clinical Investigation Plan
CRF Case Report Form
CRM Clinical Research Manager
DD Device Deficiency
GCP Good Clinical Practice
ICF Informed Cons ent Form
IRB Institutional Review Board
MHC Mölnlycke Health Care
PI Principal Investigator
PJI Periprosthetic Joint I nfection
SAE Serious Adverse Ev ent
SADE Serious Adverse Device Effect
SSI Surgical Site Infection
THR/THA Total Hip replacement/Total Hip Arthroplasty
TJA Total Joint Arthroplasty
TKR/TKA Total Knee R eplacement/Total Knee Arthroplasty
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 10(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 091.INTRODUCTION
Total joint arthroplasty is a safe and effective procedure improving the quality of  life an d 
restoring function to patients w ith arthritis of the hip and knee. Although its general succ ess is 
beyond dispute, postoperative complications such as periprosthetic joint infection (PJI) still 
occur1.
Most surgical w ounds heal rapidly w ithout complications; how ever some can become infected. 
Such infe ctions occur when microorganisms are introduced through the surgical incision as a 
result of  bacteria or fungi migration from the patient´s skin or gastrointestinal tract ,direct 
transfer from surgical instruments, equipment or hands of healthcare w orkers or via airb orne 
route.2
Every time the dressing needs to be changed, there is an increased risk of the w ound becoming 
exposed to contamination. The evidence for optimal choice of  dressing is based on chronic 
wounds and not surgical w ounds ,2However,in 2014 ,an International Consensus Meeting on 
Periprosthetic Joint Infection w as held at which delegates from various dis ciplines worldw ide 
participated and came to a consensus that an occlusive dressing after total joint arthroplasty 
(TJA) should be used.3Occlusive dressings protect the w ound from both pathogenic invasion 
and further trauma. They act as barriers and prevent t he entry of outside pathogens that m ight 
infect the w ound and delay healing. Since they conf orm to the body's contours, they are more 
likely to remain in place and offer protection from further trauma as w ell. They move as the body 
moves, making them less susceptible to shear ingand tearing during the daily activities .4
NICE (2008) guidelines on the prevention and treatment of surgical site infection and the DH 
(2007) High Impact Intervention care bundle recomm endthatdressings applied in operating 
theatre should remain in situ for at least 48 hours before removal to prevent the entry of 
microorganisms and promote healing. Dressings should be removed before this time only if 
there is excessive leakage from the dr essing. Nurses should ensure that any signs and 
symptoms of infection in patients are discussed w ith surgeons responsible f orthe care of these 
patients to ensure timely and appropriate treatment.2
Other post -operative complications are blistering and pain at dressing removal. Pain at dressing 
removal is a frequent complaint heard from patients w ho have their w ounds dressed with gauze 
dressings that have dried into their wound. Dressings that do not cause skin damage upon 
removal are now  available. The World Union of Wound Healing Societies initiative, ‘‘Principles 
of Best Practice: M inimising Pain at Dressing -Related Procedures: Implementati on of Pain 
Relieving Strategies ’’,recommends that clinicians use dres sings that minimize trauma/pain
during application and removal .5
Even blister s lead to increased pain, delayed healing andincreased susceptibility to w ound 
infection as the integrity of the skin has been breach ed. Blistering occurs w hen the dermis 
becomes s eparated f rom the epidermis, w hich is invariably the result of continued abrasion. The 
deep, finger -like projections of epidermal tissue holding the epidermis and dermis together are 
weakened, allow ing the tw oskin layers to separate . The incidence of w ound blister shas been 
reported in the literature of between 6 -24%.6
When developing postoperative w ound complications and surgical site infections this can 
increase r ecovery times, hospital stay costs and morbidit y rates .7
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 11(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09In a prospective randomized controlled study, three types of dressings (Mepore Pro, Mepilex 
Border Surgical Size and Hypafix Transparent) w ere compared in 150 consecutive subjects 
admitted for hip surgery with regard to prevalence of tape blisters. The blister prevalence w as 
significantly low er for the Mepilex Border group (4%), than for the Mepore Pro group (51%, 
p<0.01) and Hypafix group (61%, p<0.01). The total number of dressings used during the 
hospital stay w ere also significantly low er for the Mepilex Border group compared to the Mepore 
Pro and Hypafix group (p<0.01). The conclusion was that the dressing w ith a silicone adhesive 
(Mepilex Border) signi ficantly reduced the prevalence of blisters follow ing hip s urgery .8
In another open, prospective Post Market Clinical Follow -Up Study (MxB Po 01), Mepilex Border 
Post-Op was used in 49 pati ents and a standard dr essing in 11 patients.
The results indicatedthat Mepilex Border Post -Op with the high absorption capacity, flexible 
wound pad, broader border and the skin friendly Safetac®Technology le d to good stay on abilit y
(7 days ), no blisters, no skin stripping, al most no pain at dressing removal, no dressing related 
infections and no hypersensitive reaction.13
Mepilex Border Ag is a conformable self -adherent silver dressing in the Mepilex Border 
assortment. Several investigations have been conducted show ing that Mepilex Border Ag 
minimizes trauma to the w ound bed and surrounding skin upon dressing removal, has good 
exudate management,9,10reduce the number of  microorganisms,10,11,12minimizes pain to the 
patient during dressing removal, minimizes the risk of maceration and is easy to handle.9,10,11,12
The adhesive is Safetac®Technology (silicon), a unique and patented adhesive technology that 
minimiz es pain to patients and trauma to w ounds and the surrounding skin. Mepilex Border 
Post-Op Ag is an upgraded version of the Mepilex Border Ag and will be evaluated in this 
investiga tion.
The overall rationale for this investigation is to evaluate the clinical performance potential for 
Mepilex Border Post -Op Agin the ability to minimiz e the risk of skin related post -operative 
wound complications such as blistering , maceration and redness at the incision and surrounding 
skin.
1.1Risk/benefit Assessment
Incorrect dressing selection may leads to increased rates of blistering and w ound discharge. 
This, in turn, may translate into additional costs caused by the need for more dressing changes
and a prolonged hospital stay.6
Previous investigations have show n that M epilex Border Ag w ith the adhesive Safetac®
Technology is effective and skin friendly.9,10Since the Mepilex Border Post -Op Ag is an 
upgraded version of Mepilex Border Ag the performance w ill be further looked at in this 
investigation. It is believed that these upgrades w ill give both the hospital sta ff and the subject 
an even better experience and satisfaction w hen it comes to application, conformation to the 
body contours and ability to stay on.
Site staff w ill be trained on how  to use the investigational device and subjects w ill be closely 
monitored during the investigation. Adverse events (AEs), Adverse Device Effects (ADEs) 
Serious Adverse Events (SAE),  and Device Deficiencies (DD) w ill be registered throughout the 
investigation. The investigation w ill also be subjected to IRB review  and approval before any 
subjects are included.
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 12(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 092.OBJECTIVES
This investigation is undertaken to investigate the performance of a self -adhesive absorbent 
post-operative silver dressing coated w ith a soft silicone layer in subjects undergoing elective, 
primary, total hip or knee arthroplasty . 
The prim ary objective and outcome variable are show n in the table below :
Primary objective Primary outcome v ariable
To evaluate the skin damage under 
the dressing from operation day to 
last visitDamage to the incision and surroun ding skin 
from operation day to last visit in terms of:
-Blistering 
-Redness 
-Maceration 
The secondary objectives and outcome variables areshow n in the table below :
Secondary objectiv e Secondary outcome variable
To evaluate performance of the 
dressing from operation day to last 
visit-Leakage 
-Show er ability
-Dressing sticksto the staples/sutures 
-Bleeding caused by the dressing 
removal 
-Dressing w ear time (days )
-Number of dressing change s
-Residuals of the dressing material in 
the wound or surrounding s kin
-Dressing capacity of handling blood
To evaluate comfort, conformability 
and acceptability of the dressing from 
operation day to last visitNurse/investigator evaluation 
-Easeof application of the dressing
-Ease of removal of the dressing
-Conform ation to the body contours
-Overall experience (only at the last 
visit)
Subject evaluation 
-Comfort when w earing the dressing
-Ease of mobility
-Overall experience of the dressing
(only at the last visit)
To evaluate pain at dressing removal 
from operation day to last visit-Millimeter reading on visual analogue 
scales (VAS) filled in by subject
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 13(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09The safety objective and outcome variables areshown in the table below :
Safety objective Safet y outcome v ariable
To evaluate safety of the dressing by 
assessm ent of de vice deficiencies 
and adverse events, non -serious and 
serious, rated for causality-Incidence of AE/ADE/SAE/SADE/DD
-Incidence of AE/ADE/SAE/SADE/DD 
leading to withdraw al
3.CLINICAL INVESTIGA TOR(S) AND INVESTIGA TION 
ADMINISTRA TIVE STRUCTURE
3.1Staff at Inves tigation site(s)
Name and address of the PI at the investigation site is to be found in Appendix A .
3.2Mölnlycke Investigation Personnel
Role in the investigation Name Contact information
Clinical Research Manager Tina Kjellén Mölnlycke Health Care AB
Byfogdegatan 1
SE-415 05 Göteborg, SWEDEN
Phone: +46 31722 30 98
E-mail: tina.kjellen@molnlycke.com
Clinical Research Manager David Pham Molnlycke Health Care US, LLC
5550 Peachtree Parkw ay
Suite 500
Norcross, GA 30092
USA
Phone: +1 905 829 1502
E-mail: dav id.pham@molnlycke.com
Clinical Research 
AdministratorAnnika Rydström Mölnlycke Health Care AB
Byfogdegatan 1
SE-415 05 Göteborg, SWEDEN
Phone: +46 31722 3000
E-mail: annika.rydstrom@molnlycke.com
Clinical Data Manager Henrik Ahlbom Mölnlycke Health Car e AB
Byfogdegatan 1
SE-415 05 Göteborg, SWEDEN
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 14(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09Phone: +46 31722 3000
E-mail: henrik.ahlbom@molnlycke.com
Biostatistician Henrik Ahlbom Mölnlycke Health Care AB
Byfogdegatan 1
SE-415 05 Göteborg, SWEDEN
Phone: +46 31722 3000
E-mail: henrik.ahlbom@molnlyc ke.com
Global Clinical Research
DirectorMarkus Wittebo Mölnlycke Health Care AB
Byfogdegatan 1
SE-415 05 Göteborg, SWEDEN
Phone: +46 31722 3000
E-mail: markus .wittebo @molnlycke.com
3.3Other Participants
Role in the investigation Contact information
eCRF activities Pharma Consulting Group AB
Kungsängsvägen 19 
SE-753 23 Uppsala
Sweden
Phone: +46 18 430 3100
4.INVESTIGA TION PLAN AND PROCEDURES
4.1Overall Design
This single center , open, non- controlled investigation w ill be conducted at onesite ,US. 
Approx imately 20 male or f emal esubjects, 18 years or older , with a planned elective primary 
total hip or knee replacement w ill be recruited in this investigation. The primary purpose is to 
investigate if there is any skin damage under the dressing f rom operatio n day to last visit. 
Performance of the dressing as well as comfort, conformability, acceptability and pain at
dressing rem oval will also be followed -up until post-op day 7. Subjects at site number 01 are 
usually sent home on post -op day t wo or three but t his investigation will include a follow -up visit 
on post -op day 7 w hen the dressing is removed and the incision and incision site are inspected 
before termination. Ifit is not possible to schedule a visit at post -op day 7 due to weekends, it is 
ok to sche dule a visit for post -op day 5 or 6. Post -op day 7 is how ever the day to strive for.
4.2Procedures and Assessments
The investigational device shall be used only in this investigation and according to the Clinical 
Investigation Plan (CIP). The devices are for single use only and must be used according to 
instructions for use (Appendix D) . 
Follow ing Institutional Review  Board (IRB) approval and before any investigation related 
procedure, potential subjects w ill be asked to sign a written informed consent form (ICF). The 
subjects will be given sufficient tim e for the information to be read and understood. The subject 
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 15(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09will be approached and given the chance to ask any questions that have arisen after reading the 
ICF. After obtaining the subject´s written informed cons ent and verifying that the subject fulfills 
all inclusion and none of the exclusion criteria, the subject will participate in a screening visit 
and be allocated a s ubject ID . The screening visit w ill obtain information about the subject’s 
medical /surgi calhistory, concomitant medication, and factors pertaining to the scheduled 
surgical procedure. Only subjects w ho fulfi ll all inclusion and none of the exclusion criteria and 
are found eligible by the investigator, w ill be enrolled in the investigation. The subject ID (unique 
identification code) will be recorded in the site’s all relevant investigation documentation 
pertaining to that individual.
If a subject is judged to be ineligible for enro llment, the primary reason of ineligibility w ill be 
documented and the subject w ill be considered as a screening failure. Ineligible subjects w ill 
receive the standard of care at the facility and no investigational documentation w ill be collected 
for these subjects.
4.2.1 Schedule of Assessment
All variables to be obtaine d during the Investigation are to be found 4.6.1, 4.6.2, 4.6.3 and
in Appendix C.
Schedule of Assessment
Day Baseline 
(screening 
visit)Day 0
Day of 
surgeryDay 
1
1st
post 
-op 
dayDay 
2
2nd
post-
op 
dayaDay 
3
3rd
post-
op 
dayaUnscheduled 
visitbDay 7
7th
post-op 
dayTermination
Visit window/days -21 to 0 0 0 0 0 0 -2 to 0c0
Visit (number) 1 2 3 4 5 Unscheduled 6 Termination
Inclusion /Exclusion 
Criteria 
InformedConsent 
Subject ID 
Subject demography 
Skin status atincision 
site
Medical /Surgical history 
Type of surgery 
Surgical incision 
condition     
Performance of the 
dressing     
Dressing logd () () ()  
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 16(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09Day Baseline 
(screening 
visit)Day 0
Day of 
surgeryDay 
1
1st
post 
-op 
dayDay 
2
2nd
post-
op 
dayaDay 
3
3rd
post-
op 
dayaUnscheduled 
visitbDay 7
7th
post-op 
dayTermination
Medication Log       
Pain assessmen te() () ()  
Photo sf     
Nurse/investigator 
evaluationg     
Subject evaluationh    
Reason for termination 
AE/ADE /SAE/SADE /DD       
a Information will be collected at Day 3 only if the subj ect is still at the hospital and hasn´t been discharged
b If the dressing is changed prior to post -op day 7 and outside scheduled visits, an unscheduled visit will be performed.
c When possible, visit 6 should be scheduled to post -op day 7. W hen not possib le due to weekends, post -op day 5 or post -op day 6 could be scheduled. 
d Dressing application/change /removal will be documented in the Dressing log. Ability to stay on (curl up at edges and partial/complete detachment) will also be 
collected 
e Pain asses sment at dressing removal (VAS). If a dressing change is deemed necessary prior to visit 6, pain assessment should be collected
f Photo s should be taken at visit 2 ( at the incision before application of the dressing, at dressing after application of the d ressing) and if the dressing is changed at 
visit 3 -6  ( at the dressing before removal of the dressing, at the incision after removal of the dressing and at dressing ( side fac ing the incision) , if signs of 
infection and if there in an unscheduled visit
gThe nurse or the investigator will give their assessment concerning the treatment
hThe nurse or the investigator will collect the subject´s experience via interview
4.3Selection of Population for Investigation
4.3.1 Inclusion Criteria
For inclusion in the invest igation, the subjects must fulfi ll all of the belowcriteria prior to 
enrol lment: 
Screening Phase:
1.Age ≥18 years
2.Available for a follow -up visit including dressing change 7 days after surgery
3. Plan for elective primary hip or knee arthroplasty
4.Plan for inc ision size ≤18 cm
5.Provision of informed consent i.e. subject must be able to understand and sign the 
Patient Information and Consent Form
Enrol lment Phase (Day of surgery) ::
6.Undergoing elective primary arthroplasty of the hip or knee . 
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 17(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 094.3.2 Exclusion Criteria
Subject swho meet any of the below criteria will be excluded f rom the investigation:
Screening Phase:
1. Known allergy/hypersensitivity to any of the components of the dressing
2.Multi -trauma
3.Undergoing arthroplasty due to tumo r 
4.Previous incision at the same k nee or same side of the hip
5.Wound at the surgical site prior to surgery
6.Neurological deficit of operated side (hemiplegia, etc.)
7.Documented skin disease at time of enrol lment, as judged by the investigator
8.Previously enrolled in the present investigation
9.Inclusion in other ongoing investigation s at present that would preclude the subject from 
participating in this investigation as judged by the investigator 
10.Involvement in the planning and conduct of the clinical investigation (applies to all MHC
staff, investigational site staff andthird party vendor)
Enro llment Phase (Day of surgery) :
11.Dressing size does not fit the incision area (>18 cm)
12.Complications that w ould increase w ound risks if investigational dressing is applied
4.3.3 Withdraw al of Subjects from Treat ment or Assessment
Subjects are free to discontinue participation in the investigation at any time, and without 
prejudice to further treatment. Subjects w ho disc ontinue the investigation should alw ays be 
asked about the reason(s) for their discontinuation and about the presence of any Adverse 
Event/Adverse Device Effect or Device Deficiency and, if possible, be assessed by an 
investigator. Adverse Event/Adverse Device Effect should be follow ed up. 
Subjects may be w ithdraw n from investigation treatment and assessments at any time, at the 
discretion of the investigator.
Incorrectly enrolled subjects will be w ithdraw n from further investigation treatment and 
assessm ents. A subject may, how ever, continue the investigation under special circumstances 
(i.e. if  continuation of investigation treatment or follow -up actions are necessary for the subject’s 
safety and w ell-being, or if only a follow -up period remains, and the continuation of the 
investigation is not expected to be associated w ith any risk or discom fort for the subject)
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 18(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 094.4Investigational Device
4.4.1 Summary description of the Investigational Device(s)
Mepilex Border Post -Op Ag is a soft silicone foam dressing that absorbs exudates, maintains a 
moist w ound healing environment and has antim icrobial properties .The investigational device is 
a line extension under current Mepilex Border Ag 510(k) clearance (K100029).
Mepilex Border Post -Op Ag consists of a Safetac®soft silicone wound contact layer, an 
absorbent polyurethane foam pad containing a silver compound and activated carbon, a layer 
with su per absorbent polyacrylate fiber s, a non -woven an d a vapor permeable w aterproof film.
The silicone layer is covered w ith a polyethylene release film w hich is in three parts with grip 
edges for easy application .
The dre ssing is steriliz ed in ethylene oxide (EO). Further details can be found in appendix D.
For more information regarding the investigational device, instructions for use and precautions, 
please see Appendix D -Instructions for use. 
For this clinical inves tigation, M epilex Border Post -Op Ag w ill be available in the follow ing size
Device (cm) Wound pad (cm) Border (cm)
10x25 5x20 2.5
4.4.2 Labelling
MHC w ill provide the investigational medical devices to the investigation site for free. Labelling 
of the investi gational medical device w ill be performed in accordance w ith Good Manufacturing 
Practice (GMP). The labels w ill be produced in the local language and in accordance w ith local 
regulations for the US. The medical device w ill be marked with the follow ing text :
Mepilex Border Post -Op Ag
Study Code: MxB Po Ag 01
“CAUTION -Investigational Device. Limited by Federal (or United States) law to investigational 
use."
4.4.3 Accountability
The investigational devices w ill not be distributed to the investigation site until a ll agreements 
between the investigator and MHC are finalized and IRB approval has been obtained. All 
investigational devices must be kept in a secure place under appropriate storage conditions.
Use of investigational devices w ill be logged in a separate ac countability form stored in the 
Investigator Site File and be reviewed at each monitoring visit. The investigational devices may 
only be used in this clinical investigation and according to the CIP. 
The principal investigator or an authorized designee sha ll keep records documenting the 
receipt, use, return and disposal of the investigational devices .
Unused products are accounted for and returned to MHC for destruction, or destroyed locally 
upon agreement with and approval from MHC. 
Applicable documents are the “Certificate of Delivery of Investigational Device/Material” , the 
“Accountability Form ”and the “Certificate of Return and Destruction of Investigation Product ”.
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 19(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 094.4.4 Storage conditions
Investigational medical device sareto be handled and stored safely , properly and in agreement 
with the given storage instructions. Mepilex Border Post -OpAgshould be stored in dry 
conditions and protected from direct sunlig ht. A description of the appropriate storage and 
shipment conditions are specified on the investig ational medical device label and in the 
instructions for use documentation (IFU) , Appendix D .
4.4.5 Method of Assigning Subjects to Treatment Groups
The investigation is an open, non -controlled investigation and hence, all subjects who fulfil lall 
inclusion and none of the exclusion criteria w ill be enrolled to the investigation.
If a subject discontinues from the investigation, the subject ID w ill not be reused and the subject 
will not be allow ed to re -enter the investigation.
4.5Concomitant Treatments
Medication, which is considered necessary f or the subject’s safety and w ell-being, may be given 
at the discretion of the investigator. All concomitant medication and relevant treatment must be 
recorded in the appropriate section of the Case Report Form (CRF). 
Only a ntiseptics, a nticoagulant s, antibiotics and analgesics as well as skin related medication 
and those related to medical/surgical history and AEs are to be collected and reported in the 
Medication log.
4.6Performance and Safety
4.6.1 Subject Characteristics
The fol lowing subject characteristics (demographics) will be recorded in the eCRF:
-Date of birth (dd- mm-yyyy)
-Gender (f/m)
-Weight (kg)
-Height (cm)
-BMI
-Medical History
-Surgical History
-Skin Status at Incision ( type of  skin (normal, dry, flaky, oily, moist, other)
-Type of Surgery ( primary hip or knee arthroplasty, length of incision and type of incision 
closure)
-Surgical incision condition (compression over the incision)
-Drainage used (N/Y)
-Drainage placed (outside the dressing border, under the dressing border)
-Exudate level 
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 20(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09-Exudate nature
-Signs of local/ systemic infection and systemic antibiotic given for the local/systematic 
infection
4.6.2 Performance Measurements and Variables
Primary objective Outcome variable Method
To evaluate the skin damage 
from operation day to last visitDamage to the incision and 
surrounding skin (blistering, 
redness, maceration)Nurse or investigator 
assessm ent.
Secondary objective Outcome variable Method
To evaluate performance of 
the dressing from operation 
day to last visita.Incidenc e of  Leakage a.Nurse or investigator 
assessment (N/Y)
b.Show er ability b.Nurse or investigator 
assessment (NA/N/Y)
c.Dressing sticks to the 
staples/w ound closure 
strips/sutures c.Nurse or investigator 
assessment (N/Y)
d.Bleeding at dressing 
removal
e.Dress ingwear timed.Nurse or investigator 
assessment (N/Y)
e.Nurse or investigator 
assessment (days)
f.Number of dressing 
change s
g.Residuals of  the 
dressing material in 
the w ound or 
surrounding skin
h.Dressing capacity of 
handling bloodf.Nurse or investigator 
asses sment (Dressing 
log)
g.Nurse or investigator 
assessment (N/Y)
h.Nurse or investigator 
assessment (N/Y)
To evaluate comfort, 
conformability and 
acceptability of the dressing 
from operation day to last visiti.Easeof application of 
the dressingi-m. Nurse/inv estigator 
evaluation (NA/ Poor/ Good/ 
Very Good/ Excellent)
j.Ease of removal of the 
dressing
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 21(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09k.Conformation to the 
body contours
l.Overall experience
m.Comfort w hen w earing 
the dressing 
n.Ease of mobility
o.Overall experience of 
the dressingn-o. Subject evaluation (NA/ 
Poor/ Good/ Very Good/ 
Excellent)
To evaluate pain atdressing 
removal from operation day to 
last visitPain Millimeter reading on visual 
analogue scales (VAS) filled 
in by subject . The results w ill 
be transferred to the eCRF by 
the staff at the investigation 
site
4.6.3 Safety Measurements and Variables
Adverse Event (AE)/Adverse Device Effect (ADE), Serious Adverse Event (SAE)/Serious 
Adverse Device Effect (SADE) and Device Deficiencies (DD). The definition of AE, ADE, SAE, 
SADE and DD and pro cedures for reporting SAE and SADE and DD that could have led to a 
SADE are presented in section 8 of this CIP. All AE, ADE, SAE, SADE and DD must also be 
recorded in the appropriate section of the CRF. It is of utmost importance that all staff involved 
inthe investigation is familiar w ith the content of section 8. It is the responsibility of the Principal 
Investigator to ensure this.
4.6.4 Anticipated ADEs 
The follow ing events have been identified as anticipated effects in the Product Risk 
Management Record:
Wound dry out
Maceration
Infection
Pain and discomfort
Skin irritation
The conclusion of the Product Risk Management Record is as follow ing:
Based on the risk management record it can be concluded that for Mepilex Border Post -OpAg 
products, there are n o unacceptable risks of harm to the subject, the user nor third party 
involved in this device w hen used under normal condition sand for its intended use .
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 22(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 094.7Data Quality Assurance
4.7.1 Monitoring, Audits and Inspections
During the investigation, the monitor w ill have regular contacts with the investigation site. These 
contacts w ill include visits to confirm that the facilities remain adequate to specified standards 
and that the investigation site team is carrying out the procedure stated in the clinical 
investigati on plan and supports the investigator. All data must be accurately recorded in the 
CRF. Source data verification (a comparison of data in the CRF w ith the subject’s 
hospital/practice and other records at the investigation site) with direct access to record s will 
also be performed.
The monitor or other M ölnlycke Health Care (MHC) personnel w ill be available betw een visits if 
the investigator or other staff at the site needs information and/or advice. 
Authoriz ed representatives of  MHC and/or a Competent Auth ority (CA) and/or the Institutional 
Review  Board (IRB) may visit the investigation site to perform audits/inspections, including 
source data verification.
4.7.2 Training of Staff
The Principal Investigator will ensure that appropriate training relevant to the i nves tigation is 
given to the medical, nursing and other staff at the site involved and that new  information of 
relevance to the performance of this investigation is forw arded to the staff involved.
Before the first subject is entered into the investigatio n,Mölnlycke Health Care personnel will 
conduct a site initiation visit. The purpose of the visit is to provide training to the involved site 
personnel including, but not lim ited to the following items: 
Clinical investigation plan (CIP) and execution ther eof 
Use of the investigational device 
Use of the eCRF system
Study Equipment to be used
Maintenance of Investigator Site File (ISF)
The staff at the investigational site w ill sign a confirmation document that they are trained in how  
to use the investiga tional device. Only trained staff (w ho has received delegation from the PI) 
will be allow ed to apply and remove the dressings for a given subject. .
4.7.3 Data Management
The Data Management process includes all activities related to data handling regarding:
Set-up of eCRF and database
Specification of on -line checks
Data entry / Data editing
Export of data from Viedoc to SAS
Creation of  post -entry checks and listings
Reconcili ation of Serious Adverse Event (SAE), Serious Adverse Device Effect 
(SADE), Adverse Dev ise Effect (ADE) and Device Deficiency (DD)
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 23(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09Clean -file process including execution of post -entry checks and listings
Post clean -file tasks
Pharma Consulting Group will build and set up Viedoc, a web based electronic CRF system that
will be used to capture data in this investigation. The eCRF system complies w ith FDA Title 21 
CRF part 11 (ER/ES) requirement.
eCRF training will be given to appropriate personnel before/at initiation of the investigation 
site(s). 
Data entry w ill be done by investigators and ot her authorized personnel at the site(s). When 
entering data, on -line checks are incorporated in Viedoc for consistency and validation.
Pharma Consulting Group w ill support w ith a helpdesk function taking care of  system user 
questions regarding Viedoc.
Whendata has been entered authorized personnel at MHC can immediately view the data, 
send queries if necessary and lock eCRF pages when they have been validated. 
Photos w ill be uploaded in Viedoc and are marked w ith the subject ID . Uploaded photos shall 
not contain any information that can reveal the identity of the subject. All uploaded photos w ill 
be review ed by personnel at MHC and stored in the company database. All data entered in 
Viedoc w ill be encrypted. The physical database w ill be stored in Sw eden.
Programs for post -entry checks and data listings w ill be created and executed for validation of 
data. 
Completeness w ill be checked by authorized personnel at MHC so that there are no 
unexplainable empty fields in Viedoc. This is done in order to prevent t hat data being
overlooked by personnel entering the data.
A clean-file meeting will be held prior to database lock. All decisions on the evaluability of the 
data from each individual subject for the statistical analysis must be made and documented 
before l ocking the database. Readable copies o f the eCRF data will be archived in the 
Investigator Site File (ISF) at the investigation site after clean file.
Data w ill be retained for at least 10 years after investigation closure.
4.8Statistical Methods and Determi nation of Sample Size
4.8.1 Statistical Evaluation
Presentation of the data 
The results from this open, non -controlled clinical investigation w ill be presented w ith descriptive 
statistics. No hypothesis testing is planned for this investigation.
Data listings w ill be prepared for all data . Certain data w ill be collated into summary tables and 
figures. Those summary tables and figures w ill be integr ated into the body of the investigation 
report . 
Population sfor analysis
Safety population
The population for the a ssessment of safety w ill include all enrolled subjects w ho provide at 
least the baseline visit.
ITT population
The Intention to Treat (ITT) population w ill include all subjects to at least one post -enrolment 
treatment. 
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 24(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09PP population
The Per Protocol (PP) population w ill include all subjects w ithout significant protocol violations. 
Subjects identified as protocol violators w ill be documented and agreed upon before declaration 
of clean -file. 
Baseline characteristics
All variables m easured at baseline w ill be summarized for the ITT -and PP population using 
appropriate summary statistics.
Performance and safety measurement
All endpoints w ill be summariz ed as above and by visit. The result f rom the CRF w ill be 
summarized appropriately for all evaluable subject s. 
The num ber of subjects reporting one or more adverse events during the course of the 
investigation w ill be summari zed using frequency counts .
4.8.2 Determination of Sample Size
This is a descriptive i nvestigation and the number of subjects have been chosen t o be able to 
find explorative trends.
4.9Changes to the Clinical Investigation Plan
No change in the investigation procedure w ill be effected w ithout the m utual agreement of the 
Principal Investigator and M HC.
An amendment to the Investigation Plan may requi re notification or approval from IRB before 
implem entation. Local requirements must be followed.
MHC w ill distribute clinical investigation plan amendments to the Principal Investigator w ho is 
responsible for the distribution of these documents to the IRB and staff  involved at his/her site. 
5.STATEMENTS OF COMPLIANCE
5.1Ethics
5.1.1 Ethics review 
The final clinical investigation plan, including the final version of the Patient Inf ormation and 
Consent Form, must be approved or given a favorable opinion in writing by an IRB before 
enrollment of any subject into the investigation. The Principal Investigator is r esponsible for 
informing the IRB of any amendment to the investigation plan as per local requirements.
5.1.2 Ethical Conduct of the Investigation
The investigation w ill be perf ormed in accordance w ith the ethical principles that have their 
origin in the most recent version of the Declaration of Helsinki, and w ith applicable regulatory 
requirem ents. Patients, w ho are close colleagues, associates, or family members of, o r in any 
way dependent on the sponsor or the investigator, will not be included in this investigation. 
5.1.3 Patient Information and Consent Form
The Principal Investigator will ensure that the subject is given full and adequate oral and w ritten 
information abo ut the nature, purpose, possible risks and benefits of  the investigation. Subjects 
must also be notified that they are free to discontinue participation in the investigation at any 
time. The subject should be given the opportunity to ask questions and time for consideration. 
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 25(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09The subject’s signed informed consent has to be obtained before conducting any investigation 
related procedures. The original m ust be filed by the Principal Investigator. A copy of the Patient 
Information including the signed Consent Fo rm should be given to the subject.
A sample of the Patient Information and Consent Form is enclosed (Appendix B). If 
modifications are made according to local requirements, the new  version must be approved by 
MHC.
5.2Regulatory and standards
5.2.1 Regulatory review
If applicable, the final clinical investigation plan, including the final version of the Patient 
Information and Consent Form, must be approved or given a favorable opinion in w riting by a 
CA before enro llment of any subject into the investigation. MHC is responsible for informing the 
CA of any amendment to the investigation plan as per local requirements.
5.2.2 Standards and other
The most recent version of ISO 14155 is follow ed in addition to national regulations, 21 CFR 50 
Protection of Hum an Subjects, 21 CFR 56 Institutional Review  Boards and 21 CFR 54 Financial 
Disclosure.
5.2.3 Subject Data Protection
The w ritten Patient Information explains that the data w ill be stored in a computer database, 
maintaining confidentiality in accordance w ith national da ta legislati on and that authoriz ed 
representatives of M HC and/or IRB, require direct access to those parts of the hospital/practice 
records relevant to the investigation, including medical history, for verification of data. All data 
computerized by MHC will be identif ied by subject ID only.
5.3SUBJECT PROTECTION PROCEDURES
5.3.1 Procedures in Case of Medical Emergency
The Principal Investigator is responsible for ensuring that procedures and expertise are 
available to cope w ith medical emergencies during the investigation.
5.3.2 Insurance
Mölnlycke Health Care AB has product liability insurance, which also covers test products .
6.INVESTIGA TION TIMET ABLE AND TERMINA TION
Investigation start: Q12017
Inclusion completed: Q22017
Last subject out: Q2 2017
The investigation could be prema turely discontinued if the investigation site is unable to fulfil l
the inclusion period according to the Clinical Investigation Agreement.
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 26(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 097.LITERA TURE REVIEW AND REFERENCES
1.Parvizi J, Paw asarat IM , Azzam KA, et al. Periprosthetic joint infection: the ec onomic 
impact of methicillin -resistant infections. JOA 2010;25(6 Sup):103.
2.Harrington P (2014) Prevention of surgical site infection. Nursing Standard. 28, 48, 50 -58. 
Date of submission: March 7 2014; date of acceptance: April 28 2014.
3.ElieGhanem, E., H eppert, V. et al., Wound Managment. JOrthop Res32: 108–S119,
2014
4.Rheinecker,s., Wound Management: The Occlusive Dressing. J Athl Train. 1995 Jun; 
30(2): 143 -144, 146
5.Baranoski S , Ayello EA .,  Wound dressings: an evolving art and science. Adv Skin Wound 
Care. 2012 Feb;25(2):87 -92
6.Cosker, T., Elsayed, S., Gupta, S. et al. Choice of  dressing has a major impact on 
blistering and healing outcomes in orthopaedic patients. J Wound Care 2 005; 14: 1, 27 -
29.
7.Tustanow ski, J. Effect of dressing choice on outcomes after hip and knee arthroplasty: a 
literature review . J Wound Care 2009; 18: 11, 449 -454.
8.Côte M, Provost J, Denault A, Pelet S. 2010. Presentation on 66th Annual Meeting of  
Canadia n Orthopedic Association: Reduction of tape blisters af ter hip surgery; A 
prospective evaluation of  three kinds of bandages .
9.Davis , D.Use of an antimicrobial Soft Silicone Borded Foam Dressing as an Adjunctive 
Treatment w ith a Single Layer Bioengineered Dermal Tissue, Poster at SAWC 2012
10.Davies , P.Mepilex® Border Ag: A Global In -Market Evaluation (Former Follow -up of the 
intended use of Mepilex Border Ag) , 2013
11.Latenser , B.Open multi -centre investigation to evaluate signs and symptoms of local
inflamm ation/infection on chronic ulcers and partial thickness burns w hen using Mepilex
Border Ag as an anti -microbial w ound dressing. MxB Ag 01, 2012
12.Huss , F.An open, non -controlled, post- marketing investigation evaluating the experience 
ofusing a self -adhere nt antimicrobial soft silicone, silver containing, foam dressing, 
Mepilex Border Ag, in second degree burns MxB Ag, 2011
13.Zarghooni K., Lohmann C., Bredow  N., Oppermann A. , Krueger B., Wenk J., Meyer H. 
Effect of a modern dressing compared to a standard dr essing on outcome after primary 
hip and knee arthroplasty, prospective non ran domised study. Poster EWMA 2015
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 27(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 098.DEFINITIONS AND PROCEDURES FOR REPORTING OF 
ADVERSE EVENT , ADVERSE DEVICE EFFECT , SERIOUS 
ADVERSE EVENT , SERIOUS ADVERSE DEVICE EFFECT 
AND DEVI CE DEFICIENCY 
Definitions:
Device Deficiency (DD)
Inadequacy of a medical device w ith respect to its identity, quality, durability, reliability, safety or 
performance.
Note: 
Device Deficiencies include malfunctions, use errors, and inadequate labelling. 
All Device Deficiencies that might have led to a Serious Adverse Device Effect shall be reported 
in accordance with Serious Adverse Event reporting procedures, as specified below .
Adverse Event (AE) 
Any untoward medical occurrence, unintended disease or injury, or untow ard clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, w hether or not 
related to the investigational medical device
Note: 
This definition includes events related to the investigational medical dev ice or the 
comparator.
This definition includes events related to the procedures involved.
For users or other persons, this definition is restricted to events related to 
investigational medical devices.
Adverse Device Effect (ADE) 
Adverse Event related to the use of an investigational medical device 
Note: 
This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, or operation, or any malf unction of 
the investigational medical device.
This definition includes any event resulting from use error or f rom intentional misuse 
of the investigational medical device.
Serious Adverse Event (SAE)
Adverse Event that:
a) led to death,
b) led to a serious deterioration in the health of the subject, that e ither resulted in
1)a life -threatening illness or injury, or
2)a permanent impairment of a body structure or a body f unction, or
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 28(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 093)in-patient hospitalization or prolonged hospitalization or,
4)medical or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function.
c) led to foetal distress, foetal death or a congenital abnormality or birth defect.
Note:
Planned hospitalization for a pre -existing condition, or a procedure required by the CIP, w ithout 
serious deterioration in health, is not considered a serious adverse event.
Serious Adverse Device Effect (SADE)
Adverse Device Effect that has resulted in any of the consequences characteristic of a Serious 
Adverse Event.
PRO CEDURES FOR SAE AND/OR SADE REPORTING OR REPORTING OF DD THAT 
COULD HAVE LED TO A SADE
The investigator must inform Mölnlycke Health Care (MHC), w ithin 1 calender day of aw areness 
of the event. When a SAE/SADE has been entered into the eCRF by the investigator 
/authorised site staff, the eCRF system w ill automatically generate a report to: 
Clinical_Investigations_Event_Reporting@molnlycke.com .
In case of problem w iththe eCRF, a paper based version of the SAE/SADE report form 
(available in the Investigator Site File) shall be used and sent by email to: 
Clinical_Investigations_Event_Reporting@molnlycke.com .
All SAEs/SADEs that occurs during the Clinical Investigation shall be reported, w hether or not 
they are considered causally related to the investigational device.
Device Deficiencies that might have led to SADE if either a) suitable action had not been taken, 
b) if interven tion had not been made, or c) if circumstances had been less fortunate must be 
reported as a SADE.
The investigator is responsible for informing the EC/IRB and/or the Competent Authority of the 
SAE/SADE as per local requirements.
PRO CEDURES FOR DD REPORT ING 
All DD shall be reported to MHC as soon as possible, w ithout unjustified delay . If the DD m ight 
have led to a SADE the reporting requirements for SADE described above must be follow ed. 
DDs can be either subject related or non -subject related dependin g on if  the investigational 
device w as used by a subject or not. Separate forms are used for subject related and non -
Clinical Investigation Plan Document 
ID: PD -
492446Rev: 01
Title: CIP Mx B Po Ag 01Page 29(29)
Investigation Code MxB Po Ag 01 Final Version Approval date 2016 -11-15
Document template: F-167 Clinical Investigat ion Plan Rev: 09subject related DDs. When a subject related DD has been entered into the eCRF by the 
investigator /authorised site staff, the eCRF system w ill automatically generate a report to: 
Clinical_Investigations_Event_Reporting@molnlycke. 
Non-subject related DDs are reported using thepaper based report form located in the 
Investigator Site File. The completed form shall be sent by email to 
Clinical_Investigations_Event_Reporting@molnlycke.com
Causality Assessment
The relationship betw een the use of the investigational device and the occurrence of each 
AE/SAE shall be ass essed by the investigator and the sponsor and classified as investigational 
device related or not related to investigational device.
 CIP Amendment  Document ID:  PD-521925 Rev: 00 
Title: CIP Amendment 01  Page 1(6) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-11-21 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
CLINICAL INVESTIGATION PLAN (CIP)  Central AMENDMENT no 1 
Substantial  
  
INVESTIGATIONAL DEVICE:  
Mepilex Border Post -Op Ag  
INVESTIGATION TITLE:  
 
A single center, open, non -controlled investigation to evaluate the performance of a 
flexible, self -adherent absorbent silver dressing coated with a soft silicone layer 
after elective primary total hip or knee arthroplasty  
 
SITES AFFECTED BY THE AMENDMENT:  
The amendment affect all in the study  
 
 
 
 
 CIP Amendment  Document ID:  PD-521925 Rev: 00 
Title: CIP Amendment 01  Page 2(6) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-11-21 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
THE CLINICAL INVESTIGATION PLAN (CIP) IS TO BE AMENDED AS FOLLOWS:  
 
Section and page in the Clinical Investigation Plan  (CIP): 
 
CIP section: Synopsis /  Overall Design   
CIP page: 3 
 
From:  
This descriptive, prospective, non -controlled clinical  investigation  will be conducted on 
approximately 20  enrolled  subjec ts at one site in  the US. 
The target subject s are male or female, 18 years  and older , undergoing elective primary hip or 
knee  arthroplasty with a possibility to participate in a follow -up visit 7 days after surgery.  Subjects 
will consecutively be allocated to a subject ID. The subjects will be followed 1 -3 days after surgery 
and scheduled for a follow -up visit 7 days after surgery.  
 
To: 
This descriptive, prospective, non -controlled clinical  investigation  will be conducted on 
approximately 20  enrolled  subjec ts at one site in  the US. 
The target subject s are male or female, 18 years  and older , undergoing elective primary hip or 
knee  arthroplasty with a possibility to participate in a follow -up visit 7 days after surgery.  Subjects 
will consecutively be allocated to a subject ID.  
Subjects at site number 01 are usually sent home on post -op day one  (1) or two (2). If the subject 
are sent home post -op day two (2) this investigation will include a telephone follow -up on post -op 
day two (2), clinic visit on post -op day three (3) and a follow -up visit on post -op day 7 when the 
dressing is removed and the incision and incision site are inspected before termination . If the 
dressing is changed prior to post -op day 7 and outside scheduled visits, an unscheduled visit will 
be performed.  
 
CIP section: Synopsis / Schedule of Assessment  & 4.2.1 Schedule of Assessment  
CIP page: 5 & 15 
From:  
Day Baseline 
(screen ing 
visit) Day 0 
Day of 
surgery Day  
1 
1st 
post -
op 
day Day  
2 
2nd 
post-
op 
daya Day  
3 
3rd 
post-
op 
daya Unscheduled 
visitb Day 
7 
7th 
post-
op 
day Termination  
Visit window/days  -21 to 0  0 0 0 0 0 -2 to 
0c 0 
Visit (number)  1 2 3 4 5 Unscheduled  6 Termination  
 CIP Amendment  Document ID:  PD-521925 Rev: 00 
Title: CIP Amendment 01  Page 3(6) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-11-21 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
Day Baseline 
(screen ing 
visit) Day 0 
Day of 
surgery Day  
1 
1st 
post -
op 
day Day  
2 
2nd 
post-
op 
daya Day  
3 
3rd 
post-
op 
daya Unscheduled 
visitb Day 
7 
7th 
post-
op 
day Termination  
Inclusion/ Exclusion 
Criteria          
Informed Consent          
Subject ID          
Subject demography          
Skin status at incision 
site         
Medical /Surgical 
history          
Type of surgery          
Surgical incision 
condition          
Performance of the 
dressing          
Dressing logd   () () ()    
Medication Log          
Pain assessmente   () () ()    
Photosf         
Nurse/investigator 
evaluationg             
Subject evaluationh         
Reason for termination          
AE/ADE/SAE/SADE/DD          
a Information will  be collected at Day 3 only if the subject is still at the hospital  and hasn´t been discharged  
b If the dressing is changed prior to post -op day  7 and outside scheduled visits, an unscheduled visit will be performed.  
c When possible, visit 6 should be scheduled to post -op day 7. When not possible due to weekends, post -op day 5 or post -op day 6 could be scheduled.  
d Dressing application/ change /removal will be documented in the Dressing log. Ability to stay on (curl up at edges and partial/complete detachment) will also be 
collected  
e Pain assessment at dressing removal  (VAS). If a dressing change is deemed necessary prior to visit 6, pain assessment should be collected  
f Photo s should be taken at visit 2 ( at the incision before application of the dressing, at dressing after application of the dress ing) and if the dress ing is changed at visit 
3-6  ( at the dressing before removal of the dressing, at the incision after removal of the dressing and at dressing ( side fac ing the incision) , if  signs of infection  and if 
there in an unscheduled visit  
g The nurse or the investi gator will give their assessment concerning the treatment  
h The nurse or the investigator will collect the subject´s experience via interview  
 
 CIP Amendment  Document ID:  PD-521925 Rev: 00 
Title: CIP Amendment 01  Page 4(6) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-11-21 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
 
 
To: 
Day Baseline 
(screening 
visit) Day 0 
Day of 
surgery Day 1  
1st 
post -
op 
day Day  
2 
2nd 
post-
op 
daya Day  
2 
2nd post-
op  
Telephone 
Follow -Up i   Day 3  
3rd 
post-
op 
daya Un-
scheduled 
visitb Day 
7 
7th 
post-
op 
day Term -
ination  
Visit window/days  -21 to 0  0 0 0 0 0 0 -2 to 
0c 0 
Visit (number)  1 2 3 4 4 5 Un-
scheduled  6 Term -
ination  
Inclusion/ Exclusion 
Criteria           
Informed Consent           
Subject ID           
Subject demography           
Skin status at incision 
site          
Medical /Surgical history           
Type of surgery           
Surgical incision 
condition           
Performance of the 
dressing           
Dressing logd   () ()  ()    
Medication Log           
Pain assessmente   () ()  ()    
Photosf          
Nurse/investigator 
evaluationg              
Subject evaluationh          
Reason for termination           
AE/ADE/SAE/SADE/DD           
a Information will  be collected at Day 3 only if the subject is still at the hospital  and hasn´t been discharged  
b If the dressing is changed prior to post -op day 7 and outside scheduled visits, an unscheduled visit will be performed.  
c When possible, visit 6 should be scheduled to post -op day 7. When not possible due to weekends, post -op day 5 or post -op day 6 could be scheduled.  
d Dressing application/ change /removal  will be documented in the Dr essing log. Ability to stay on (curl up at edges and partial/complete detachment) will also be 
collected  
e Pain assessment at dressing removal  (VAS). If a dressing change is deemed necessary prior to visit 6, pain assessment should be collected  
 CIP Amendment  Document ID:  PD-521925 Rev: 00 
Title: CIP Amendment 01  Page 5(6) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-11-21 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
f Photo s should be taken at visit 2 ( at the incision before application of the dressing, at dressing after application of the dressing ) and if the dressing is changed at visit 
3-6  ( at the dressing before removal of the dressing, at the incision after removal of t he dressing and at dressing ( side facing the incision) , if  signs of infection  and if 
there in an unscheduled visit  
g The nurse or the investigator will give their assessment concerning the treatment  
h The nurse or the investigator will collect the subjec t´s experience via interview  
i Telephone Follow -Up 
 
CIP section: 4.1 Overall Design  
CIP page: 14 
From:  
This single center , open, non -controlled investigation will be conducted at one site in  the US. 
Approximately 20  male or female  subjects,  18 years  or older , with a planned elective primary total 
hip or knee replacement will be recruited in this investigation. The primary purpose is to investigate 
if there is any skin damage under the dressing from operation day to last visit. Performance of the 
dressing as well as comfort, conformability,  acceptability  and pain at  dressing removal  will also be 
followed -up until post -op day 7. Subjects at site number 01 are usually sent home on post -op day 
two or three but this investigation will include a follow -up visit on post -op day 7 when the dressing 
is removed and the incision and incision site are inspected before termination. If it is n ot possible to 
schedule a visit at post -op day 7 due to weekends, it is ok to schedule a visit for post -op day 5 or 6. 
Post-op day 7 is however the day to strive for.  
 
To: 
This single center, open, non -controlled investigation will be conducted at one site  in the US . 
Approximately 20 male or female subjects, 18 years or older, with a planned elective primary total 
hip or knee replacement will be recruited in this investigation. The primary purpose is to investigate 
if there is any skin damage under the dressing from operation day to last visit. Performance of the 
dressing as well as comfort, conformability, acceptability and pain at dressing removal  will also be 
followed -up until post -op day 7. Subjects at site number 01 are usually sent home on post -op day 
one (1) or two (2). If the subject are sent home post -op day two (2) this investigation will include a 
telephone follow -up on post -op day two (2), clinic visit on post -op day three (3) and a follow -up visit 
on post -op day 7 when the dressing is removed  and the incision and incision site are inspected 
before termination . If the dressing is changed prior to post -op day 7 and outside scheduled visits, 
an unscheduled visit will be performed . 
If it is not possible to schedule a visit at post -op day 7 due to weekends, it is ok to schedule a visit 
for post -op day 5 or 6. Post -op day 7 is however the day to strive for.  
 
CIP section: 4.1 Labelling  
CIP page: 18 
From: 
MHC will provide the investigational medical devices to the investigation site for free. Labelling  of 
the investigational medical device will be performed in accordance with Good Manufacturing 
Practice (GMP). The labels will be produced in the local language and in accordance with local 
regulations for the US.  The medical device will be marked with the  following text:  
Mepilex Border Post -Op Ag  
Study Code: MxB Po Ag 01  
 CIP Amendment  Document ID:  PD-521925 Rev: 00 
Title: CIP Amendment 01  Page 6(6) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-11-21 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
“CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational 
use."  
 
 
To: 
MHC will provide the investigational medical devices to the investigation site f or free. Labelling of 
the investigational medical device will be performed in accordance with Good Manufacturing 
Practice (GMP). The labels will be produced in the local language and in accordance with local 
regulations for the US.  The medical device will be marked with the following text:  
Mepilex Border Post -Op Ag  
Study Code: MxB Po Ag 01  
Investigational Device - Not for Resale  
 
REASON FOR MAKING THE AMENDMENT:  
Reason for making the amendment:  
According to standard of care on site no 01.  Subjects are usually sent home on post -op day one 
(1) and not post -op day three  (3). The clinical investigation plan was updated to fit the standard of 
care on site no 01.  
Correcting typing errors: discrepancie s between the label specification and labelling section in the 
clinical investigation plan . 
 
ACTIONS TO BE TAKEN:  
Investigator at the site will be provided with the amendment and signature will be collected.  
The Amendment will be sent to the IRB for approv al according to local procedures.  
 
 
&,3$PHQGPHQW'RFXPHQW,' 3'5HY
7LWOH&,3$PHQGPHQW1R3DJH
,QYHVWLJDWLRQ&RGH 0[%3R$J)LQDO 9HUVLRQ &,3$SSURYDOGDWH 
$PHQGPHQW)LQDO9HUVLRQ $PHQGPHQW$SSURYDOGDWH 

'RFXPHQWWHPSODWH)&,3$PHQGPHQW 5HY 

&/,1,&$/,19(67,*$7,213/$1&,3&HQWUDO$0(1'0(17QR 
6XEVWDQWLDO 

,19(67,*$7,21$/'(9,&(
0HSLOH[%RUGHU3RVW2S$J 
,19(67,*$7,217,7/(

$VLQJOHFHQWHURSHQQRQ FRQWUROOHGLQYHVWLJDWLRQWRHYDOXDWH WKHSHUIRUPDQFHRID
IOH[LEOHVHOIDGKHUHQWDEVRUEH QWVLOYHUGUHVVLQJFRDWHGZLWKD VRIWVLOLFRQHOD\HU
DIWHUHOHFWLYHSULPDU\WRWDOKLSRUNQHHDUWKURSODVW\ 

6,7(6$))(&7('%<7+($0(1'0(17
7KHDPHQGPHQWDIIHFWDOOLQWKHVWXG\


&,3$PHQGPHQW'RFXPHQW,' 3'5HY
7LWOH&,3$PHQGPHQW1R3DJH
,QYHVWLJDWLRQ&RGH 0[%3R$J)LQDO 9HUVLRQ &,3$SSURYDOGDWH 
$PHQGPHQW)LQDO9HUVLRQ $PHQGPHQW$SSURYDOGDWH 

'RFXPHQWWHPSODWH)&,3$PHQGPHQW 5HY 

7+(&/,1,&$/,19(67,*$7,213/$1&,3,672%($0(1'('$6)2//2 :6

6HFWLRQDQGSDJHLQWKH&OLQLFD O,QYHVWLJDWLRQ3ODQ&,3

&,3VHFWLRQ6\QRSVLV2YHUDOO'HVLJQ
&,3SDJH

)URP
6XEMHFWVDWVLWHQXPEHUDUH XVXDOO\VHQWKRPHRQSRVWRSGD\ RQHRUWZR,IWKHVXEMHFW
DUHVHQWKRPHSRVWRSGD\WZR WKLVLQYHVWLJDWLRQZLOOLQFOX GHDWHOHSKRQHIROORZXSRQSRVWRS
GD\WZRFOLQLFYLVLWRQSRVW RSGD\WKUHHDQGDIROORZ XSYLVLWRQSRVWRSGD\ZKHQWKH
GUHVVLQJLVUHPRYHGDQGWKHLQFLVL RQDQGLQFLVLRQ VLWHDUHLQVS HFWHGEHIRUHWHUPLQDWLRQ,IWKH
GUHVVLQJLVFKDQJHGSUL RUWRSRVWRSGD\DQGRXWVLGHVFKHGXOH GYLVLWVDQXQVFKHGXOHGYLVLWZLOO
EHSHUIRUPHG 
7R
6XEMHFWVDWVLWHQXPEHUDUH XVXDOO\VHQWKRPHRQSRVWRSGD\ RQHRUWZR,IWKHVXEMHFW
DUHVHQWKRPHSRVWRSGD\WZR WKLVLQYHVWLJDWLRQZLOOLQFOX GHDWHOHSKRQHIROORZXSRQSRVWRS
GD\WZRFOLQLFYLVLWRQSRVW RSGD\WKUHHGD\D QGDIROORZXSYLVLWRQSRVWRSGD\
ZKHQWKHGUHVVLQJLVUHPRYHGDQGW KHLQFLVLRQDQ GLQFLVLRQVLWH DUHLQVSHFWHGEHIRUH WHUPLQDWLRQ,I
WKHGUHVVLQJLVFKDQJHGSULRU WRSRVWRSGD\DQGRXWVLGHVFKH GXOHGYLVLWVDQ XQVFKHGXOHGYLVLW
ZLOOEHSHUIRUPHG
&,3VHFWLRQ2 YHUDOO'HVLJQ
&,3SDJH)URP
7KLVVLQJOHFHQWHURSHQQRQ FRQWUROOHGLQYHVWLJDWLRQZLOOEH FRQGXFWHGDWRQHVLWHLQWKH86
$SSUR[LPDWHO\PDOHRUIHPDOHVXEMHFWV\HDUVRUROGHUZL WKDSODQQHGHOHFWLYHSULPDU\WRWDO
KLSRUNQHHUHSODFHPHQWZLOOEH UHFUXLWHGLQWKLVLQYHVWLJDWLRQ 7KHSULPDU\SXUSRVHLVWRLQYHVWLJDWH
LIWKHUHLVDQ\VNLQGDPDJHXQGHUWKHGUHVVLQJIURPRSHUDWLRQG D\WRODVWYLVLW3HUIRUPDQFHRIWKH
GUHVVLQJDVZHOODVFRPIRUWFRQIRUPDELOLW\DFFHSWDELOLW\DQG SDLQDWGUHVVLQJUHPRYDOZLOODOVREH
IROORZHGXSXQWLOSRVWRSGD\ 6XEMHFWVDWVLWHQXPEHUDUH XVXDOO\VHQWKRPHRQSRVWRSGD\
RQHRUWZR,IWKHVXEMHF WDUHVHQWKRPHSRVWRSGD\WZ RWKLVLQYHVWLJDWLRQZLOOLQFOXGHD
WHOHSKRQHIROORZXSRQSRVWRSGD\WZRFOLQLFYLVLWRQSRV WRSGD\WKUHHDQGDIROORZXSYLVLW
RQSRVWRSGD\ZKHQWKHGUHVVL QJLVUHPRYHGDQGWKHLQFLVLRQ DQGLQFLVLRQVLW HDUHLQVSHFWHG
EHIRUHWHUPLQDWLRQ,IWKHGUHVVLQJLVFKDQJHGSULRUWRSRVWRS GD\DQGRXWVLGHVFKHGXOHGYLVLWV
DQXQVFKHGXOHGYLVLWZLOOEHSHUIRUPHG
,ILWLVQRWSRVVLEOHWRVFKHG XOHDYLVLWDWSRVWRSGD\GXH WRZHHNHQGVLWLVRNWRVFKHGXOHDYLVLW
IRUSRVWRSGD\RU3RVWRSGD\LVKRZHYHUWKHGD\WRVWU LYHIRU



&,3$PHQGPHQW'RFXPHQW,' 3'5HY
7LWOH&,3$PHQGPHQW1R3DJH
,QYHVWLJDWLRQ&RGH 0[%3R$J)LQDO 9HUVLRQ &,3$SSURYDOGDWH 
$PHQGPHQW)LQDO9HUVLRQ $PHQGPHQW$SSURYDOGDWH 

'RFXPHQWWHPSODWH)&,3$PHQGPHQW 5HY 

7R
7KLVVLQJOHFHQWHURSHQQRQ FRQWUROOHGLQYHVWLJDWLRQZLOOEH FRQGXFWHGDWRQHVLWHLQWKH86
$SSUR[LPDWHO\PDOHRUIHPDOHVXEMHFWV\HDUVRUROGHUZL WKDSODQQHGHOHFWLYHSULPDU\WRWDO
KLSRUNQHHUHSODFHPHQWZLOOEH UHFUXLWHGLQWKLVLQYHVWLJDWLRQ 7KHSULPDU\SXUSRVHLVWRLQYHVWLJDWH
LIWKHUHLVDQ\VNLQGDPDJHXQGHUWKHGUHVVLQJIURPRSHUDWLRQG D\WRODVWYLVLW3HUIRUPDQFHRIWKH
GUHVVLQJDVZHOODVFRPIRUWFRQIRUPDELOLW\DFFHSWDELOLW\DQG SDLQDWGUHVVLQJUHPRYDOZLOODOVREH
IROORZHGXSXQWLOSRVWRSGD\ 6XEMHFWVDWVLWHQXPEHUDUH XVXDOO\VHQWKRPHRQSRVWRSGD\
RQHRUWZR,IWKHVXEMHF WDUHVHQWKRPHSRVWRSGD\WZ RWKLVLQYHVWLJDWLRQZLOOLQFOXGHD
WHOHSKRQHIROORZXSRQSRVWRSGD\WZRFOLQLFYLVLWRQSRV WRSGD\WKUHHGD\ DQGD
IROORZXSYLVLWRQSRVWRSGD \ZKHQWKHGUHVVLQJLVUHPRYHGD QGWKHLQFLVLRQDQ GLQFLVLRQVLWHDUH
LQVSHFWHGEHIRUHWHUPLQDWLRQ,IWKHGUHVVLQJLVFKDQJHGSULRU WRSRVWRSGD\DQGRXWVLGH
VFKHGXOHGYLVLWVDQXQVFKHGXOHGYLVLWZLOOEHSHUIRUPHG
,ILWLVQRWSRVVLEOHWRVFKHG XOHDYLVLWDWSRVWRSGD\GXH WRZHHNHQGVLWLVRNWRVFKHGXOHDYLVLW
IRUSRVWRSGD\RU3RVWRSGD\LVKRZHYHUWKHGD\WRVWU LYHIRU

&,3VHFWLRQ6\QRSVLV6FK HGXOHRI$VVHVVPHQW	 6FKHGXOHRI$VVHVVPHQW 
&,3SDJH	
)URP
'D\ %DVHOLQH
VFUHHQLQJ
YLVLW'D\
'D\RI
VXUJHU\'D\
VW
SRVW
RS
GD\'D\

QG
SRVW
RS
GD\D'D\

QGSRVW
RS
7HOHSKRQH
)ROORZ8SL'D\
UG
SRVW
RS
GD\D8Q
VFKHGXOHG
YLVLWE'D\

WK
SRVW
RS
GD\7HUP
LQDWLRQ
9LVLWZLQGRZGD\V  WR    WR
F
9LVLWQXPEHU   8Q
VFKHGXOHG7HUP
LQDWLRQ
,QFOXVLRQ([FOXVLRQ
&ULWHULD9 9      
,QIRUPHG&RQVHQW 9       
6XEMHFW,' 9       
6XEMHFWGHPRJUDSK\ 9       
6NLQVWDWXVDWLQFLVLRQ
VLWH 9      
0HGLFDO6XUJLFDOKLVWRU\ 9       
7\SHRIVXUJHU\  9      
6XUJLFDOLQFLVLRQ
FRQGLWLRQ 999  9 9 9
3HUIRUPDQFHRIWKH
GUHVVLQJ 999  9 9 9
'UHVVLQJORJG  999 9 9 9
&,3$PHQGPHQW'RFXPHQW,' 3'5HY
7LWOH&,3$PHQGPHQW1R3DJH
,QYHVWLJDWLRQ&RGH 0[%3R$J)LQDO 9HUVLRQ &,3$SSURYDOGDWH 
$PHQGPHQW)LQDO9HUVLRQ $PHQGPHQW$SSURYDOGDWH 

'RFXPHQWWHPSODWH)&,3$PHQGPHQW 5HY 

'D\ %DVHOLQH
VFUHHQLQJ
YLVLW'D\
'D\RI
VXUJHU\'D\
VW
SRVW
RS
GD\'D\

QG
SRVW
RS
GD\D'D\

QGSRVW
RS
7HOHSKRQH
)ROORZ8SL'D\
UG
SRVW
RS
GD\D8Q
VFKHGXOHG
YLVLWE'D\

WK
SRVW
RS
GD\7HUP
LQDWLRQ
0HGLFDWLRQ/RJ 9 99999 9 9
3DLQDVVHVVPHQWH  99 9 9 9
3KRWRVI  999  9 9 9
1XUVHLQYHVWLJDWRU
HYDOXDWLRQJ 999 9 9 9
6XEMHFWHYDOXDWLRQK  99  9 9 9
5HDVRQIRUWHUPLQDWLRQ       9
$($'(6$(6$'('' 9 99999 9 9
D,QIRUPDWLRQZLOOEHFROOHFWHGDW'D\RQO\LIWKHVXEMHFWLV VWLOODWWKHKRVSLWDODQGKDVQWEHHQGLVFKDUJHG
E,IWKHGUHVVLQJLVFKDQJHGSULRUWRSRVWRSGD\DQGRXWVLGH VFKHGXOHGYLVLWVDQXQVFKHGXOHGYLVLWZLOOEHSHUIRUPHG
F:KHQSRVVLEOHYLVLWVKRXOGEHVFKHGXOHGWRSRVWRSGD\ :KHQQRWSRVVLEOHGXHWRZHHNHQGVSRVWRSGD\RUSRVWRSGD\ FRXOGEHVFKHGXOHG
G'UHVVLQJDSSOLFDWLRQFKDQJHUHPRYDOZLOOEHGRFXPHQWHGLQWKH 'UHVVLQJORJ$ELOLW\WRVWD\RQFXUOXSDWHGJHVDQGSDUWLDO FRPSOHWHGHWDFKPHQWZLOODOVREH
FROOHFWHGH3DLQDVVHVVPHQWDWGUHVVLQJUHPRYDO9$6,IDGUHVVLQJFKDQ JHLVGHHPHGQHFHVVDU\SULRUWRYLVLWSDLQDVVHVVPHQWVKRXOG EHFROOHFWHG
I3KRWRVVKRXOGEHWDNHQDWYLVLWDWWKHLQFLVLRQEHIRUHDS SOLFDWLRQRIWKHGUHVVLQJDWGUHVVLQJDIWHUDSSOLFDWLRQRIWKH GUHVVLQJDQGLIWKHGUHVVLQJLVFKDQJHGDWYLVLW
DWWKHGUHVVLQJEHIRUHUHPRYDORIWKHGUHVVLQJDWWKHL QFLVLRQDIWHUUHPRYDORIWKHGUHVVLQJDQGDWGUHVVLQJVLGHID FLQJWKHLQFLVLRQLIVLJQVRILQIHFWLRQDQGLI
WKHUHLQDQXQVFKHGXOHGYLVLW
J7KHQXUVHRUWKHLQYHVWLJDWRUZLOOJLYHWKHLUDVVHVVPHQWFRQF HUQLQJWKHWUHDWPHQW
K7KHQXUVHRUWKHLQYHVWLJDWRUZLOOFROOHFWWKHVXEMHFWVH[SHUL HQFHYLDLQWHUYLHZ 
7R
'D\ %DVHOLQH
VFUHHQLQJ
YLVLW'D\
'D\RI
VXUJHU\'D\
VW
SRVW
RS
GD\'D\

QG
SRVW
RS
GD\D'D\

QGSRVW
RS
7HOHSKRQH
)ROORZ8SL'D\
UG
SRVW
RS
GD\D8Q
VFKHGXOHG
YLVLWE'D\

WK
SRVW
RS
GD\7HUP
LQDWLRQ
9LVLWZLQGRZGD\V  WR    WR
F
9LVLWQXPEHU    8Q
VFKHGXOHG7HUP
LQDWLRQ
,QFOXVLRQ([FOXVLRQ
&ULWHULD9 9      
,QIRUPHG&RQVHQW 9       
6XEMHFW,' 9       
6XEMHFWGHPRJUDSK\ 9       
6NLQVWDWXVDWLQFLVLRQ
VLWH 9      
0HGLFDO6XUJLFDOKLVWRU\ 9       
&,3$PHQGPHQW'RFXPHQW,' 3'5HY
7LWOH&,3$PHQGPHQW1R3DJH
,QYHVWLJDWLRQ&RGH 0[%3R$J)LQDO 9HUVLRQ &,3$SSURYDOGDWH 
$PHQGPHQW)LQDO9HUVLRQ $PHQGPHQW$SSURYDOGDWH 

'RFXPHQWWHPSODWH)&,3$PHQGPHQW 5HY 

'D\ %DVHOLQH
VFUHHQLQJ
YLVLW'D\
'D\RI
VXUJHU\'D\
VW
SRVW
RS
GD\'D\

QG
SRVW
RS
GD\D'D\

QGSRVW
RS
7HOHSKRQH
)ROORZ8SL'D\
UG
SRVW
RS
GD\D8Q
VFKHGXOHG
YLVLWE'D\

WK
SRVW
RS
GD\7HUP
LQDWLRQ
7\SHRIVXUJHU\  9      
6XUJLFDOLQFLVLRQ
FRQGLWLRQ 999  9 9 9
3HUIRUPDQFHRIWKH
GUHVVLQJ 999  9 9 9
'UHVVLQJORJG  999 9 9 9
0HGLFDWLRQ/RJ 9 99999 9 9
3DLQDVVHVVPHQWH  99 9 9 9
3KRWRVI  999  9 9 9
1XUVHLQYHVWLJDWRU
HYDOXDWLRQJ 999 9 9 9
6XEMHFWHYDOXDWLRQK  99  9 9 9
5HDVRQIRUWHUPLQDWLRQ       9
$($'(6$(6$'('' 9 99999 9 9
D,QIRUPDWLRQZLOOEHFROOHFWHGDW'D\RQO\LIWKHVXEMHFWLV VWLOODWWKHKRVSLWDODQGKDVQWEHHQGLVFKDUJHG
E,IWKHGUHVVLQJLVFKDQJHGSULRUWRSRVWRSGD\DQGRXWVLGH VFKHGXOHGYLVLWVDQXQVFKHGXOHGYLVLWZLOOEHSHUIRUPHG
F:KHQSRVVLEOHYLVLWVKRXOGEHVFKHGXOHGWRSRVWRSGD\ :KHQQRWSRVVLEOHGXHWRZHHNHQGVSRVWRSGD\RUSRVWRSGD\ FRXOGEHVFKHGXOHG
G'UHVVLQJDSSOLFDWLRQFKDQJHUHPRYDOZLOOEHGRFXPHQWHGLQWKH 'UHVVLQJORJ$ELOLW\WRVWD\RQFXUOXSDWHGJHVDQGSDUWLDO FRPSOHWHGHWDFKPHQWZLOODOVREH
FROOHFWHGH3DLQDVVHVVPHQWDWGUHVVLQJUHPRYDO9$6,IDGUHVVLQJFKDQ JHLVGHHPHGQHFHVVDU\SULRUWRYLVLWSDLQDVVHVVPHQWVKRXOG EHFROOHFWHG
I3KRWRVVKRXOGEHWDNHQDWYLVLWDWWKHLQFLVLRQEHIRUHDS SOLFDWLRQRIWKHGUHVVLQJDWGUHVVLQJDIWHUDSSOLFDWLRQRIWKH GUHVVLQJDQGLIWKHGUHVVLQJLVFKDQJHGDWYLVLW
DWWKHGUHVVLQJEHIRUHUHPRYDORIWKHGUHVVLQJDWWKHL QFLVLRQDIWHUUHPRYDORIWKHGUHVVLQJDQGDWGUHVVLQJVLGHID FLQJWKHLQFLVLRQLIVLJQVRILQIHFWLRQDQGLI
WKHUHLQDQXQVFKHGXOHGYLVLW
J7KHUHVHDUFKVWDIIZLOOJLYHWKHLUDVVHVVPHQWFRQFHUQLQJWKH WUHDWPHQW
K7KHUHVHDUFKVWDIIZ LOOFROOHFWWKHVXEMHFWVH[SHULHQFHYLDLQWHUYLHZ
L7HOHSKRQH)ROORZ8S





&,3$PHQGPHQW'RFXPHQW,' 3'5HY
7LWOH&,3$PHQGPHQW1R3DJH
,QYHVWLJDWLRQ&RGH 0[%3R$J)LQDO 9HUVLRQ &,3$SSURYDOGDWH 
$PHQGPHQW)LQDO9HUVLRQ $PHQGPHQW$SSURYDOGDWH 

'RFXPHQWWHPSODWH)&,3$PHQGPHQW 5HY 


5($621)250$.,1*7+($0(1'0(17
5HDVRQIRUPDNLQJWKHDPHQGPHQW
$FFRUGLQJWRVWDQGDUGRIFDUHRQV LWHQRWKHVXUJHULHVDUH XVXDOO\SHUIRUPHG0RQGD\DQG
7KXUVGD\VWRDGGDYLVLWZLQGRZRIRQHGD\RQSRVWRSGD\WKUH HZLOODYRLGWKHQHHGWRUHWXUQ
IRUDIROORZXSWRWKHFOLQLFGXULQJWKHZHHNHQG7KHFOLQLFDO LQYHVWLJDWLRQSODQZDVXSGDWHGWRILW
WKHVWDQGDUGRIFDUHRQVLWHQR WKHUHFUXLWPHQWKDVQRWVWD UWHG

$&7,21672%(7$.(1
,QYHVWLJDWRUDWWKHVLWHZLOOEHSURYLGHGZLWKWKHDPHQGPHQWDQ GVLJQDWXUHZLOOEHFROOHFWHG
7KH$PHQGPHQWZLOOEHVHQWWRWKH,5%IRUDSSURYDO DFFRUGLQJWRORFDOSURFHGXUHV 

 CIP Amendment  Document ID:  PD-522356 Rev: 00 
Title: CIP Non -substantial amendment 01  Page 1(4) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-12-01 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
CLINICAL INVESTIGATION PLAN (CIP)  Central AMENDMENT no 2 
Non Substantial  
  
INVESTIGATIONAL DEVICE:  
Mepilex Border Post -Op Ag  
INVESTIGATION TITLE:  
 
A single center, open, non -controlled investigation to evaluate the performance of a 
flexible, self -adherent absorbent silver dressing coated with a soft silicone layer 
after elective primary total hip or knee arthroplasty  
 
SITES AFFECTED BY THE AMENDMENT:  
The amendment affect all in the study  
 
 
 
 
 CIP Amendment  Document ID:  PD-522356 Rev: 00 
Title: CIP Non -substantial amendment 01  Page 2(4) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-12-01 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
THE CLINICAL INVESTIGATION PLAN (CIP) IS TO BE AMENDED AS FOLLOWS:  
 
Section and page in the Clinical Investigation Plan:  
CIP section: Synopsis / Schedule of Assessment  & 4.2.1 Schedule of Assessment  
CIP page: 5 & 15 
 
From:  
Day Baseline 
(screening 
visit) Day 0 
Day of 
surgery Day 1  
1st 
post -
op 
day Day  
2 
2nd 
post-
op 
daya Day  
2 
2nd post-
op  
Telephone 
Follow -Up i   Day 3  
3rd 
post-
op 
daya Un-
scheduled 
visitb Day 
7 
7th 
post-
op 
day Term -
ination  
Visit window/days  -21 to 0  0 0 0 0 0 0 -2 to 
0c 0 
Visit (number)  1 2 3 4 4 5 Un-
scheduled  6 Term -
ination  
Inclusion/ Exclusion 
Criteria           
Informed Consent           
Subject ID           
Subject demography           
Skin status at incision 
site          
Medical /Surgical history           
Type of surgery           
Surgical incision 
condition           
Performance of the 
dressing           
Dressing logd   () ()  ()    
Medication Log           
Pain assessmente   () ()  ()    
Photosf          
Nurse/investigator 
evaluationg              
Subject evaluationh          
Reason for termination           
AE/ADE/SAE/SADE/DD           
 CIP Amendment  Document ID:  PD-522356 Rev: 00 
Title: CIP Non -substantial amendment 01  Page 3(4) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-12-01 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
a Information will  be collected at Day 3 only if the subject is still at the hospital and hasn´t been discharged  
b If the dressing is changed prior to post -op day 7 and outside scheduled visits, an unscheduled visit will be performed.  
c When possible, visit 6 should be scheduled to post -op day 7. When not possible due to weekends, post -op day 5 or post -op day 6 could be scheduled.  
d Dressing application/ change /removal  will be documented in the Dressing log. Ability to stay on (curl up at edges and partial/complete detachment) will also be 
collected  
e Pain assessment at dressing removal  (VAS). If a dressing change is deemed necessary prior to visit 6, pain assessment should be collected  
f Photo s should be taken at visit 2 ( at the incision before application of the dressing, at dressing after applicat ion of the dressing) and if the dressing is changed at visit 
3-6  ( at the dressing before removal of the dressing, at the incision after removal of the dressing and at dressing ( side fac ing the incision) , if  signs of infection  and if 
there in an unsched uled visit  
g The nurse or the investigator will give their assessment concerning the treatment  
h The nurse or the investigator will collect the subject´s experience via interview  
i Telephone Follow -Up 
 
To: 
Day Baseline 
(screening 
visit) Day 0 
Day of 
surgery Day 1  
1st 
post -
op 
day Day  
2 
2nd 
post-
op 
daya Day  
2 
2nd post-
op  
Telephone 
Follow -Up i   Day 3  
3rd 
post-
op 
daya Un-
scheduled 
visitb Day 
7 
7th 
post-
op 
day Term -
ination  
Visit window/days  -21 to 0  0 0 0 0 0 0 -2 to 
0c 0 
Visit (number)  1 2 3 4 4 5 Un-
scheduled  6 Term -
ination  
Inclusion/ Exclusion 
Criteria           
Informed Consent           
Subject ID           
Subject demography           
Skin status at incision 
site          
Medical /Surgical history           
Type of surgery           
Surgical incision 
condition           
Performance of the 
dressing           
Dressing logd   () ()  ()    
Medication Log           
Pain assessmente   () ()  ()    
Photosf          
Nurse/investigator 
evaluationg              
 CIP Amendment  Document ID:  PD-522356 Rev: 00 
Title: CIP Non -substantial amendment 01  Page 4(4) 
Investigation Code  MxB Po Ag 01 Final Version  CIP Approval d ate 2016-11-15 
Amendment Final Version  Amendment Approval date  2016-12-01 
 
Document template: F-168 CIP Amendment  Rev: 04  
 
Day Baseline 
(screening 
visit) Day 0 
Day of 
surgery Day 1  
1st 
post -
op 
day Day  
2 
2nd 
post-
op 
daya Day  
2 
2nd post-
op  
Telephone 
Follow -Up i   Day 3  
3rd 
post-
op 
daya Un-
scheduled 
visitb Day 
7 
7th 
post-
op 
day Term -
ination  
Subject evaluationh          
Reason for termination           
AE/ADE/SAE/SADE/DD           
a Information will be collected at Day 3 at the hospital or as outpatient visit  
b If the dressing is changed prior to post -op day 7 and  outside scheduled visits, an unscheduled visit will be performed.  
c When possible, visit 6 should be scheduled to post -op day 7. When not possible due to weekends, post -op day 5 or post -op day 6 could be scheduled.  
d Dressing application/ change /removal  will be documented in the Dressing log. Ability to stay on (curl up at edges and partial/complete detachment) will also be 
collected  
e Pain assessment at dressing removal  (VAS). If a dressing change is deemed necessary prior to visit 6, pain assessment sho uld be collected  
f Photo s should be taken at visit 2 ( at the incision before application of the dressing, at dressing after application of the dress ing) and if the dressing is changed at visit 
3-6  ( at the dressing before removal of the dressing, at the incision after removal of the dressing and at dressing ( side facing the incision) , if  signs of infection  and if 
there in an unscheduled visit  
g The nurse or the investigator will give their assessment concerning the treatment  
h The nurse or the investiga tor will collect the subject´s experience via interview  
i Telephone Follow -Up 
 
REASON FOR MAKING THE AMENDMENT:  
Typing  error, inconsistency between Overall Design and Scheduled of Assessment in the CIP 
body.  
 
 
 
ACTIONS TO BE TAKEN:  
Protocol updated with the corrections.  
 
 